🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million infections per year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in the same week. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

Based on results released by a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The research included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Medical professionals directly involved have voiced hope. Access to a one-pill regimen like this is described as a "revolutionary step" for gonorrhoea control. This is deemed vital to reduce the burden of the disease for individuals and to prevent the spread of untreatable gonorrhoea globally.